Compare Bristol-Myers Squibb Co (BMY) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Teucrium Corn Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $132.45B), while Teucrium Corn Fund trades at $17.69. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Teucrium Corn Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| BMY | CORN | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $65.89 | $19.12 |
52-Week Low | $42.60 | $16.46 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.
The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
